Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAUWILOID vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Rauwiloid (alseroxylon) is a rauwolfia alkaloid that depletes catecholamines and serotonin from postganglionic sympathetic nerve endings and the central nervous system by inhibiting vesicular monoamine transporter (VMAT). This leads to reduced peripheral vascular resistance and decreased sympathetic outflow, resulting in antihypertensive and antipsychotic effects.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Hypertension (mild to moderate),Psychiatric disorders (e.g., schizophrenia, anxiety) – historically used
Hypertension
2 mg orally twice daily, adjusted based on response; maximum 4 mg twice daily.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Terminal elimination half-life is approximately 10–12 hours. Clinical context: Requires twice-daily dosing for sustained antihypertensive effect; steady-state achieved in 2–3 days.
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Primarily hepatic via cytochrome P450 enzymes (CYP2D6 and CYP3A4); undergoes extensive first-pass metabolism.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Primarily renal excretion of metabolites; ~60–80% of a dose is eliminated in urine as metabolites, with <1% as unchanged drug. Biliary/fecal excretion accounts for ~15%.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Approximately 90% bound to plasma proteins, primarily albumin and alpha1-acid glycoprotein.
~90%, primarily to albumin
Approximately 1.6 L/kg. Clinical meaning: Indicates extensive tissue distribution beyond plasma volume; consistent with peripheral binding and accumulation in tissues.
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral: Approximately 30–50% due to first-pass metabolism.
Oral: 50–60% (extensive first-pass metabolism)
Not recommended in patients with GFR <30 m L/min; for GFR 30-60 m L/min, reduce dose by 50%.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: use is contraindicated.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Not recommended for pediatric use; safety and efficacy not established.
Not recommended for pediatric use; safety in children under 12 years not established.
Start at 1 mg orally once daily; increase slowly with close monitoring of blood pressure.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
None
None
May cause depression (including suicidal ideation), bradycardia, orthostatic hypotension, nasal congestion, and gastrointestinal disturbances. Use with caution in patients with history of depression, peptic ulcer disease, or colitis. Avoid abrupt discontinuation to prevent rebound hypertension.
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Hypersensitivity to rauwolfia alkaloids, history of depression (especially with suicidal tendencies), active peptic ulcer disease, ulcerative colitis, pheochromocytoma, and concurrent use with MAO inhibitors.
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid excessive intake of tyramine-rich foods (e.g., aged cheeses, cured meats, fermented products) as Rauwiloid may potentiate pressor effects; limit sodium intake to enhance antihypertensive effect; avoid large amounts of caffeine.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
No adequate studies in pregnant women. Animal reproduction studies have not been conducted with Rauwiloid (alseroxylon). Use in first trimester: unknown risk. Second and third trimesters: may cause fetal bradycardia, hypotension, and hypothermia if used near term. Avoid use in pregnancy unless clearly needed.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Not known whether alseroxylon is excreted in human milk. Due to potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug. M/P ratio not available.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
No specific dose adjustments established for pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) may affect drug levels; however, due to limited data, dose should be individualized and titrated to clinical response.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
Rauwiloid (alseroxylon) is a rauwolfia alkaloid used for mild to moderate hypertension; its antihypertensive effect is due to depletion of catecholamines from peripheral sympathetic nerve endings; onset is slow (weeks) and prolonged; common side effects include nasal congestion, bradycardia, and depression; avoid in patients with history of depression or peptic ulcer disease; may cause sodium and water retention; taper dose to avoid rebound hypertension.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take this medication exactly as prescribed; do not stop suddenly as this may cause a rapid increase in blood pressure.,Avoid alcohol and other central nervous system depressants as they can worsen drowsiness or dizziness.,You may experience nasal congestion, dry mouth, or slowed heart rate; report any signs of depression or mood changes.,Rise slowly from sitting or lying positions to prevent dizziness or fainting.,This medication may take several weeks to achieve full effect; continue taking it even if you feel well.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAUWILOID vs ALDORIL 15, answered by our medical review team.
RAUWILOID is a Antihypertensive that works by Rauwiloid (alseroxylon) is a rauwolfia alkaloid that depletes catecholamines and serotonin from postganglionic sympathetic nerve endings and the central nervous system by inhibiting vesicular monoamine transporter (VMAT). This leads to reduced peripheral vascular resistance and decreased sympathetic outflow, resulting in antihypertensive and antipsychotic effects.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAUWILOID and ALDORIL 15 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAUWILOID is: 2 mg orally twice daily, adjusted based on response; maximum 4 mg twice daily.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAUWILOID and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAUWILOID is classified as Category C. No adequate studies in pregnant women. Animal reproduction studies have not been conducted with Rauwiloid (alseroxylon). Use in first trimester: unknown risk. Second and third trim. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.